Market closedNon-fractional

Seres Therapeutics/MCRB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Ticker

MCRB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

233

MCRB Metrics

BasicAdvanced
$123M
Market cap
-
P/E ratio
-$0.62
EPS
2.14
Beta
-
Dividend rate
$123M
2.14
1.677
1.204
-343.751
-358.537
-4.85%
-15.74%
153.67%
0.852
-2.06
-2.06
-1.351
2,380.87%
-72.59%
60.39%
-20.34%

What the Analysts think about MCRB

Analyst Ratings

Majority rating from 7 analysts.
Buy

MCRB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$40M
-2.67%
Profit margin
0.00%
NaN%

MCRB Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.78%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.36
-$0.37
-$0.32
-$0.27
-
Expected
$0.53
-$0.50
-$0.50
-$0.34
-$0.28
Surprise
-32.57%
-26.21%
-35.63%
-20.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Seres Therapeutics stock?

Seres Therapeutics (MCRB) has a market cap of $123M as of July 06, 2024.

What is the P/E ratio for Seres Therapeutics stock?

The price to earnings (P/E) ratio for Seres Therapeutics (MCRB) stock is 0 as of July 06, 2024.

Does Seres Therapeutics stock pay dividends?

No, Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Seres Therapeutics dividend payment date?

Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders.

What is the beta indicator for Seres Therapeutics?

Seres Therapeutics (MCRB) has a beta rating of 2.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Seres Therapeutics stock

Buy or sell Seres Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing